Abstract
Cancer cells depend on multiple driver alterations whose oncogenic effects can be suppressed by drug combinations. Here, we provide a comprehensive resource of precision combination therapies tailored to oncogenic coalterations that are recurrent across patient cohorts. To generate the resource, we developed Recurrent Features Leveraged for Combination Therapy (REFLECT), which integrates machine learning and cancer informatics algorithms. Using multiomic data, the method maps recurrent coalteration signatures in patient cohorts to combination therapies. We validated the REFLECT pipeline using data from patient-derived xenografts, in vitro drug screens, and a combination therapy clinical trial. These validations demonstrate that REFLECT-selected combination therapies have significantly improved efficacy, synergy, and survival outcomes. In patient cohorts with immunotherapy response markers, DNA repair aberrations, and HER2 activation, we have identified therapeutically actionable and recurrent coalteration signatures. REFLECT provides a resource and framework to design combination therapies tailored to tumor cohorts in data-driven clinical trials and preclinical studies.
Original language | English (US) |
---|---|
Pages (from-to) | 1542-1559 |
Number of pages | 18 |
Journal | Cancer discovery |
Volume | 12 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2022 |
ASJC Scopus subject areas
- Oncology
MD Anderson CCSG core facilities
- Functional Proteomics Reverse Phase Protein Array Core
- Bioinformatics Shared Resource
- Clinical and Translational Research Center
- Precision Oncology Decision Support